在局部前列腺癌管理中使用杜塔:REDEEM随机,双盲,安慰剂对照试验
Neil E Fleshner1, M Scott Lucia, Blair Egerdie
1Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada. neil.fleshner@utoronto.ca
Lancet (London, England)
|January 27, 2012
概括
在积极监测的男性中,杜他显著降低了前列腺癌的进展. 这种5α-减少酶抑制剂显示出作为低风险前列腺癌患者的辅助疗法的前景.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 研究杜塔斯特在治疗低风险前列腺癌中的作用.
- 专注于正在积极监测前列腺癌进展的男性.
研究的目的:
- 评估杜塔斯特在预防前列腺癌进展方面的安全性和有效性.
- 评估杜塔斯特作为积极监测协议的辅助剂.
主要方法:
- 一个为期3年的随机,双盲,安慰剂对照试验.
- 涉及302名患有低体积的男性,格里森得分为5-6前列腺癌.
- 参与者每天接受杜塔斯特0.5毫克或安慰剂,随后进行活检.
主要成果:
- 杜塔胺剂减少了前列腺癌进展的38%,而安慰剂组的48% (HR 0.62,p=0.009).
- 两组之间的不良事件是相似的,心血管事件或癌症死亡人数没有增加.
- 一些男性经历了性副作用或乳房变化.
结论:
- 杜塔斯特可能是积极监测低风险前列腺癌男性的有益补充.
- 这项研究支持杜塔斯特在有效管理早期前列腺癌方面的潜力.
相关概念视频
01:11Blinding
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
01:20Disorders of the Male Reproductive System
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...